IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11041014 B1

PDFFull Text
Date of Patent:
Jun. 22, 2021

Filed:

Oct. 27, 2017

Lactoferrin/albumin fusion protein and production method therefor

Applicant:

S & K Biopharma, Inc., Kawasaki, JP;

Inventors:

Atsushi Sato, Kanagawa, JP;

Shinji Kagaya, Kanagawa, JP;

Assignee:

S & K Biopharma, Inc., Kawasaki, JP;

Attorney:

Faegre Drinker Biddle & Reath LLP

Primary Examiner:

Maryam Monshipouri

Int. Cl.
CPC ...
C07K 14/79 (2006.01); C12N 15/62 (2006.01); C12N 15/82 (2006.01); C07K 14/765 (2006.01); A61P 35/00 (2006.01); A61K 38/40 (2006.01); C12N 5/10 (2006.01); C12P 21/02 (2006.01); A61P 43/00 (2006.01); A61P 39/04 (2006.01); C07K 19/00 (2006.01); A61K 38/38 (2006.01); A61P 9/10 (2006.01); C12N 15/09 (2006.01); A01K 67/027 (2006.01);
U.S. Cl.
CPC ...
C07K 14/765 (2013.01); A01K 67/027 (2013.01); A61K 38/38 (2013.01); A61K 38/40 (2013.01); A61P 9/10 (2018.01); A61P 35/00 (2018.01); A61P 39/04 (2018.01); A61P 43/00 (2018.01); C07K 14/79 (2013.01); C07K 19/00 (2013.01); C12N 5/10 (2013.01); C12N 15/09 (2013.01); C12P 21/02 (2013.01); C07K 2319/31 (2013.01);
Abstract

The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.

Find Patent Forward Citations

Loading…